StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $1.58 | $1.50 | -4.75% | 2.0M |
| 05-18 | $1.53 | $1.46 | -4.58% | 1.3M |
| 05-19 | $1.48 | $1.43 | -3.38% | 1.4M |
| 05-20 | $1.46 | $1.50 | +2.74% | 1.0M |
| 05-21 | $1.53 | $1.52 | -0.84% | 0.5M |
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q1 2025 2025-03-31 |
|---|---|---|
Revenue | $238.00K | $0.00 |
Operating Income | $-23.66M | $-20.52M |
Net Income | $-26.07M | $-20.76M |
EPS (Diluted) | $-0.20 | $-0.31 |
Total Assets | $193.73M | $61.88M |
Total Liabilities | $157.69M | $68.01M |
Cash & Equivalents | $71.32M | $45.09M |
Free Cash Flow OCF − CapEx | $-16.10M | $-13.96M |
Shares Outstanding | 117.79M | 53.46M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.